The early diagnosis product for acute myocardial infarction, developed jointly with the subsidiary HBI, reached the commercialization stage and applied for a new medical technology to the Ministry of Health and Welfare.
This product is a product whose clinical research results have been published in the American Journal of Clinical Pathology and obtained approval from the Ministry of Food and Drug Safety by HBI and GeneMatrix plans to commercialize it in earnest this time.
Myocardial infarction is a disease with a high mortality rate when early diagnosis and treatment are delayed because there are many other diseases with similar chest pain patterns, so a diagnostic technology that can detect quickly and accurately is required.
Heart-type fatty acid-binding protein (h-FABP), which is used in the developed new product, has the property of being released into the blood more rapidly than troponin, which is an existing biomarker in case of myocardial injury, and has been known to be useful as a biomarker for early diagnosis of acute myocardial infarction. . By using a small amount of blood, it is possible to quickly analyze it with an automated analyzer, which is expected to be used in an emergency field.